Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer

Deng, Tuo; Li, Jialiang; He, Bangjie; Chen, Bin; Chen, Zi-Yan; Zheng, Jiuyi; Shi, Zhehao; Zhang, Tan; Deng, Liming; Yu, Haitao; Yang, Jinhuan; Wu, Lijun; Shan, Yunfeng; Yu, Zhengping; Chen, Xiaolei; Wang, Yi; Chen, Gang

doi:10.1007/s12072-021-10279-3

Cited by 30 publications

(38 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This phenomenon may be related to the dysregulation of intestinal flora and the reduction of probiotics, such as Bifidobacterium and BSH-rich bacteria ( 75 , 76 ). The specific gut microbiota community of patients with HCC and its correlation with markers of inflammatory response make the gut microbiota show remarkable potential for early detection of HCC ( 77 – 80 ). Based on these endless research achievements, scientists have never stopped exploring how to control the further development and metastasis of HCC.…”

Section: Gut Microbiota and Hepatobiliary Principal Diseasesmentioning

confidence: 99%

The gut microbiota: A new perspective for tertiary prevention of hepatobiliary and gallbladder diseases

Huang

Yang²,

Li³

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

The gut microbiota is a complex ecosystem that has coevolved with the human body for hundreds of millions of years. In the past 30 years, with the progress of gene sequencing and omics technology, the research related to gut microbiota has developed rapidly especially in the field of digestive system diseases and systemic metabolic diseases. Mechanical, biological, immune, and other factors make the intestinal flora form a close bidirectional connection with the liver and gallbladder, which can be called the “gut–liver–biliary axis.” Liver and gallbladder, as internal organs of the peritoneum, suffer from insidious onset, which are not easy to detect. The diagnosis is often made through laboratory chemical tests and imaging methods, and intervention measures are usually taken only when organic lesions have occurred. At this time, some people may have entered the irreversible stage of disease development. We reviewed the literature describing the role of intestinal flora in the pathogenesis and biotherapy of hepatobiliary diseases in the past 3–5 years, including the dynamic changes of intestinal flora at different stages of the disease, as well as the signaling pathways involved in intestinal flora and its metabolites, etc. After summarizing the above contents, we hope to highlight the potential of intestinal flora as a new clinical target for early prevention, early diagnosis, timely treatment and prognosis of hepatobiliary diseases.

show abstract

Section: Gut Microbiota and Hepatobiliary Principal Diseasesmentioning

confidence: 99%

The gut microbiota: A new perspective for tertiary prevention of hepatobiliary and gallbladder diseases

Huang

Yang²,

Li³

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…In a case-control study, Zhang et al performed high-throughput sequencing of the 16S rRNA from the fecal samples from 53 patients with CCA, 47 patients with cholelithiasis, and 40 healthy controls, and proposed a predictive model based on four enriched genera (Bacteroides, Muribaculaceae_unclassified, Muribaculum, and Alistipes) for the better diagnosis of CCA (102). Similarly, a classification model consisting of eight genera was constructed to classify CCA, HCC, and healthy controls (103).…”

Section: Microbiome and Ccamentioning

confidence: 99%

Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances

Qin

Yuan²,

Huang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Hepatobiliary tumors, which include cholangiocarcinoma, hepatocellular carcinoma (HCC), and gallbladder cancer, are common cancers that have high morbidity and mortality rates and poor survival outcomes. In humans, the microbiota is comprised of symbiotic microbial cells (10-100 trillion) that belong to the bacterial ecosystem mainly residing in the gut. The gut microbiota is a complicated group that can largely be found in the intestine and has a dual role in cancer occurrence and progression. Previous research has focused on the crucial functions of the intestinal microflora as the main pathophysiological mechanism in HCC development. Intestinal bacteria produce a broad range of metabolites that exhibit a variety of pro- and anticarcinogenic effects on HCC. Therefore, probiotic alteration of the gut microflora could promote gut flora balance and help prevent the occurrence of HCC. Recent evidence from clinical and translational studies suggests that fecal microbiota transplant is one of the most successful therapies to correct intestinal bacterial imbalance. We review the literature describing the effects and mechanisms of the microbiome in the gut in the context of HCC, including gut bacterial metabolites, probiotics, antibiotics, and the transplantation of fecal microbiota, and discuss the potential influence of the microbiome environment on cholangiocarcinoma and gallbladder cancer. Our findings are expected to reveal therapeutic targets for the prevention of hepatobiliary tumors, and the development of clinical treatment strategies, by emphasizing the function of the gut microbiota.

show abstract

“…Currently, some studies have highlighted the connection between ICC development and gut microbiota dysbiosis (Jia et al, 2020;Deng et al, 2022). For example, Jia et al discovered that ICC patients had higher levels of alpha-diversities and betadiversities and higher abundances of Lactobacillus, Actinomyces, Peptostreptococcaceae, and Alloscardovia compared with normal individuals (Jia et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

“…For example, Jia et al discovered that ICC patients had higher levels of alpha-diversities and betadiversities and higher abundances of Lactobacillus, Actinomyces, Peptostreptococcaceae, and Alloscardovia compared with normal individuals (Jia et al, 2020). Next, Deng et al found that a diagnostic model constructed by intestinal bacteria significantly differentiated among healthy controls, hepatocellular carcinoma patients, and ICC patients (Deng et al, 2022). However, the role of microbial components other than gut bacteria, such as fungi, in ICC has not been explored, in part because of their relatively low abundance and the lack of well-characterized reference genomes (Parfrey et al, 2011;Underhill and Iliev, 2014).…”

Section: Introductionmentioning

confidence: 99%

Alterations of gut mycobiota profiles in intrahepatic cholangiocarcinoma

Zhang

Chen²,

Chai³

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

ObjectiveIntrahepatic cholangiocarcinoma (ICC) is a silent liver malignancy with an increasing incidence. Gut mycobiota plays a crucial role in benign liver diseases; however, its correlation with ICC remains elusive. This study aimed to elucidate fungal differences in patients with ICC compared to healthy controls.MethodsThe 40 fecal samples from 23 ICC patients and 17 healthy controls were collected and analyzed using ITS2 rDNA sequencing. Obtaining the OTUs and combining effective grouping, we carried out the biodiversity and composition of the fungi, as well as FUNGuild functional annotation.ResultsOur results revealed the presence of intestinal fungal dysbiosis with significant enrichment of opportunistic pathogenic fungi such as Candida and C. albicans, and significant depletion of the beneficial fungus Saccharomyces cerevisiae in ICC patients compared with healthy controls. Alpha-diversity analysis demonstrated that patients with ICC showed decreased fungal diversity compared to healthy controls. Beta diversity analysis indicated that the two groups exhibited significant segregated clustering. Besides, C. albicans was found to be significantly more abundant in the ICC patients with TNM stage III-IV than those with stage I-II. The FUNGuild functional classification predicted that pathotrophs were the most abundant taxon in the ICC group, well above their abundance in healthy controls.ConclusionThis study indicates that dysbiosis of the fecal mycobiome might be involved in ICC development. Further research into gut fungi may contribute to new therapeutic options for ICC patients.

show abstract

Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer

Cited by 30 publications

References 51 publications

The gut microbiota: A new perspective for tertiary prevention of hepatobiliary and gallbladder diseases

The gut microbiota: A new perspective for tertiary prevention of hepatobiliary and gallbladder diseases

Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances

Alterations of gut mycobiota profiles in intrahepatic cholangiocarcinoma

Contact Info

Product

Resources

About